The UK regulator, the MHRA, has become the first to approve a new type of on-site COVID-19 test.
VMD Health & Alveo Technologies’ be.well™ Isothermal PCR achieves a level of accuracy comparable to the gold standard laboratory (PCR) tests, using a small handheld intuitive to use digital device that can be used on-site with no laboratory, delivering a result in less than one hour.
The technology uses a small swab to the front of the nose, making the test more comfortable and lowering sampling errors.
The test is brought to the UK and Europe by VMD Health, a group with a 20-year history in care home diagnostics and developed by Alveo Technologies (Alveo), a pioneering biotech company from California. The test is available for use by trained personnel in a professional setting in the European and UK markets.
Professor Martin Green OBE, CEO, Care England, said: “Reliable, fast and accurate testing is essential for care homes. As the largest representative body for independent providers of adult social care, we welcome technology to enable care homes, residents, staff and visitors to have the necessary confidence in testing procedures. Even with the vaccine roll-out apace it is clear that testing and PPE will remain part of daily life.”
Anoop Maini, a former NHS regulator and Executive Chairman, VMD Health, added: “VMD is excited to bring the be.well™ test to Europe and International markets. There has been careful evaluation in the UK in London & Hampshire NHS Trusts to give us confidence it works as well as we hoped. The test is an important advance – both digitally connected & the small swab makes the test easy to take.”